Pricing Log in Create free account
Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue
+268.4%
EPS
+73.8%
Free cash flow
+81.1%
Total debt
+0.27%

Quarter to September 2026, against a year earlier

112.70 3.94 +3.62%
Market cap
$23.9B
P/E
0.0×
Fwd P/E
−64.6×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insmed, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 6:59 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 7, 2026: 18 added · 63 removed · 40 modified; 10 with only figures updated; 3 moved without change

  1. Modified · OVERVIEW

    We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates, and technologies. For a more complete discussion of our business, strategy, products and pipeline, see Part I, Item 1, “Business,” of our Annual Report on Form 10-K for the year ended December 31, 2025.

120 more changes in this Item, word by word, in Powerpack.